Abbott Laboratories (ABT) : Roanoke Asset Management Corp Ny reduced its stake in Abbott Laboratories by 0.32% during the most recent quarter end. The investment management company now holds a total of 72,651 shares of Abbott Laboratories which is valued at $3,265,662 after selling 233 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.Abbott Laboratories makes up approximately 1.44% of Roanoke Asset Management Corp Ny’s portfolio.
Other Hedge Funds, Including , Investors Capital Advisory Services boosted its stake in ABT in the latest quarter, The investment management firm added 312 additional shares and now holds a total of 10,106 shares of Abbott Laboratories which is valued at $454,265. Abbott Laboratories makes up approx 0.09% of Investors Capital Advisory Services’s portfolio.Public Employees Retirement Association Of Colorado reduced its stake in ABT by selling 21,875 shares or 6.67% in the most recent quarter. The Hedge Fund company now holds 306,252 shares of ABT which is valued at $13,704,777. Abbott Laboratories makes up approx 0.11% of Public Employees Retirement Association Of Colorado’s portfolio.Parthenon reduced its stake in ABT by selling 507 shares or 1.03% in the most recent quarter. The Hedge Fund company now holds 48,552 shares of ABT which is valued at $2,120,266. Abbott Laboratories makes up approx 0.52% of Parthenon’s portfolio.Ct Financial Advisors reduced its stake in ABT by selling 729 shares or 17.08% in the most recent quarter. The Hedge Fund company now holds 3,540 shares of ABT which is valued at $148,291. Abbott Laboratories makes up approx 0.09% of Ct Financial Advisors’s portfolio.
Abbott Laboratories closed down -0.24 points or -0.53% at $45.02 with 76,57,947 shares getting traded on Monday. Post opening the session at $45.06, the shares hit an intraday low of $44.88 and an intraday high of $45.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.